GleamWall
中文EN

MNOV MEDICINOVA INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1226616 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY12.2%
TTM EPS YoY16.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,232.2%
Net margin-1,127.0%
FCF margin-1,047.7%
EBITDA margin-1,230.3%

Returns

ROE-24.8%
ROA-22.7%
ROIC (approx.)-78.4%
Asset turnover0.02x

Leverage & solvency

Liabilities / assets9.2%
Debt / equity0.00x
Current ratio8.75x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.93x
Accruals ratio-1.6%
Payout ratio—
Capex / revenue1.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$138,555$458,439$186,984$151,739$123,319$134,599——
R&D expense$1.10M$900,000$1.20M$1.40M$1.50M$2.00M$1.70M$1.80M
SG&A expense$1.87M$1.83M$1.59M$1.55M$1.81M$1.44M$1.36M$1.28M
Operating income-$3.06M-$2.54M-$2.84M-$3.09M-$3.38M-$3.61M-$3.20M-$3.18M
Net income-$2.84M-$2.31M-$2.59M-$2.80M-$3.05M-$3.28M-$2.86M-$2.81M
EBITDA-$3.06M-$2.54M-$2.83M-$3.09M-$3.38M-$3.60M-$3.20M-$3.18M
EPS (basic)-0.06-0.05-0.05—-0.06-0.07-0.06—
EPS (diluted)-0.06-0.05-0.05—-0.06-0.07-0.06—
Weighted avg. shares (diluted)49.38M49.22M49.22M—49.05M49.05M49.05M—
Balance sheet
Cash & equivalents$29.26M$25.42M$27.33M$30.81M$32.56M$34.26M$36.57M$40.36M
Receivables$600,584$0$245,100$0$0$134,599—$0
Current assets$30.23M$25.92M$28.15M$30.99M$32.92M$35.12M$37.68M$41.07M
PP&E, net$6,457$9,829$14,878$8,340$12,933$15,361$20,386$25,507
Goodwill$9.60M$9.60M$9.60M$9.60M$9.60M$9.60M$9.60M$9.60M
Total assets$45.24M$40.43M$42.70M$45.60M$47.58M$49.82M$52.43M$55.88M
Current liabilities$3.46M$2.96M$3.10M$3.80M$3.34M$2.65M$2.13M$2.96M
Total liabilities$4.15M$3.16M$3.30M$4.02M$3.61M$2.97M$2.50M$3.37M
Shareholders' equity$41.09M$37.27M$39.41M$41.59M$43.96M$46.86M$49.93M$52.50M
Shares outstanding51.23M49.22M49.22M49.22M49.05M49.05M49.05M49.05M
Cash flow statement
Operating cash flow-$2.39M-$1.92M-$3.47M-$2.02M-$1.70M-$2.31M-$3.78M-$1.93M
Capital expenditure$0$0$10,825$0$2,899$0$0-$2
Free cash flow-$2.39M-$1.92M-$3.48M-$2.02M-$1.71M-$2.31M-$3.78M-$1.93M
Investing cash flow$0$0-$10,825$0-$2,899$0$0$1
Financing cash flow———$244,018————
Depreciation & amortization$3,419$5,020$4,260$4,555$5,303$5,064$5,177$5,177
Stock-based compensation$430,879$176,767$407,761$180,563$157,692$204,897$285,943$263,993

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.